Evidence map›Paper›PMID 34098986›Full record

ReviewVirology journal2021

A comprehensive review on clinical and mechanistic pathophysiological aspects of COVID-19 Malady: How far have we come?

Baila Shakaib, Tanzeel Zohra, Aamer Ikram, Muhammad Bin Shakaib, Amna Ali, Adnan Bashir, Muhammad Salman, Mumtaz Ali Khan, Jamil Ansari

Abstract readReview
In one paragraph

Review in Virology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. [Omicron Variant of SARS-CoV-2 and Its Potential Impact on Dental Practice].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Baila ShakaibRawal Institute of Health Sciences, Islamabad, Pakistan.
Tanzeel ZohraNational Institute of Health, Islamabad, Pakistan. t.zohra@nih.org.pk.ORCID 0000-0002-0489-8538
Aamer IkramNational Institute of Health, Islamabad, Pakistan.
Muhammad Bin ShakaibCMH Medical College, Lahore, Pakistan.
Amna AliNational Institute of Health, Islamabad, Pakistan.
Adnan BashirNational Institute of Health, Islamabad, Pakistan.
Muhammad SalmanNational Institute of Health, Islamabad, Pakistan.
Mumtaz Ali KhanNational Institute of Health, Islamabad, Pakistan.
Jamil AnsariNational Institute of Health, Islamabad, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since its outbreak in 2019, the coronavirus disease (COVID-19) has become a pandemic, affecting more than 52 million people and causing more than 1 million mortalities globally till date. Current research reveals a wide array of disease manifestations and behaviors encompassing multiple organ systems in body and immense systemic inflammation, which have been summarized in this review. Data from a number of scientific reviews, research articles, case series, observational studies, and case reports were retrieved by utilizing online search engines such as Cochrane, PubMed, and Scopus from December 2019 to November 2020. The data for prevalence of signs and symptoms, underlying disease mechanisms and comorbidities were analyzed using SPSS version 25. This review will discuss a wide range of COVID-19 clinical presentations recorded till date, and the current understanding of both the underlying general as well as system specific pathophysiologic, and pathogenetic pathways. These include direct viral penetration into host cells through ACE2 receptors, induction of inflammosomes and immune response through viral proteins, and the initiation of system-wide inflammation and cytokine production. Moreover, peripheral organ damage and underlying comorbid diseases which can lead to short term and long term, reversible and irreversible damage to the body have also been studied. We concluded that underlying comorbidities and their pathological effects on the body contributed immensely and determine the resultant disease severity and mortality of the patients. Presently there is no drug approved for treatment of COVID-19, however multiple vaccines are now in use and research for more is underway.

Indexed as

COVID-19COVID-19 Drug TreatmentAntiviral AgentsComorbidityHumansPandemicsRisk FactorsSeverity of Illness IndexAntiviral AgentsCOVID-19Entry mechanismManifestationsPathologyVaccine

Identifiers

PMID34098986
PMCPMC8182739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.